Presently, the clinical approach to managing BC predominantly hinges on well-established clinicopathological factors and molecular markers, such as the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) [4, 5]. This evidence concerns the gene ERBB2 and breast cancer.